Form 4: Alnylam CSO Kevin Fitzgerald Reports Stock Sales and PSU Vesting

Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, reports the vesting of performance-based stock units and subsequent sales of common stock to cover tax obligations and under a pre-arranged trading plan.

Summary

• Kevin Fitzgerald, CSO & EVP, Head of Research at Alnylam Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• On February 13, 2025, Fitzgerald vested 2,103 shares of common stock from a performance-based stock unit (PSU) granted in 2021, contingent on Alnylam achieving non-GAAP operating income profitability by December 31, 2025.
• From February 14 to February 18, 2025, Fitzgerald sold a total of 1,704 shares of common stock at prices ranging from $250.21 to $264.87.
• These sales were conducted both to cover tax withholding obligations and pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 10, 2024.
• Fitzgerald also acquired 537 shares through the company's 401(k) matching contribution program.
• Following these transactions, Fitzgerald directly owns 12,881 shares and indirectly owns 537 shares through a managed account.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The vesting of PSUs is a positive sign, but the subsequent stock sales could be viewed with slight caution. The use of a 10b5-1 plan suggests a planned and orderly approach to managing personal finances.

Positives

• The vesting of the PSU indicates that Alnylam publicly reported achievement of non-GAAP operating income profitability for a 12-month calendar year, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 13, 2025.
• The reporting person acquired 537 shares of ALNY common stock under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.

Negatives

• The sale of shares, even partially for tax obligations, could be interpreted negatively by some investors.

Risks

• Continued stock sales by insiders could put downward pressure on the stock price.
• The achievement of future performance metrics related to stock units is not guaranteed.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting of the PSU is contingent on Alnylam achieving certain performance metrics.

Industry Context

Insider transactions are common in the pharmaceutical industry, particularly following the vesting of stock options or performance-based units. Monitoring these transactions can provide insights into management's perspective on the company's future prospects.

Comparison to Industry Standards

• It's common for executives at publicly traded companies like Alnylam to utilize 10b5-1 trading plans to diversify their holdings and avoid accusations of insider trading.
• The vesting of performance-based stock units is a standard practice in the biotech industry to incentivize executives to achieve specific financial or operational goals, similar to compensation structures at companies like Amgen and Gilead.
• The size and frequency of the stock sales are not unusual for an executive at a company of Alnylam's size, and are often driven by personal financial planning needs and tax considerations.

Stakeholder Impact

• Shareholders may be interested in insider trading activity as an indicator of management's confidence in the company.
• Employees may view the vesting of PSUs as a positive sign of the company's performance.

Key Dates

Keywords

Form 4, insider trading, stock sales, Alnylam, ALNY, Fitzgerald, PSU, Rule 10b5-1, beneficial ownership